2016 ACVIM Forum Research Abstract Program

Conclusion: These results are consistent therefore with the hypothesis that overexpression of CCL2 and recruitment of large numbers of monocytes may explain in part the aggressive metastatic nature of canine hemangiosarcoma. Moreover, these findings suggest that immunotherapeutic interventions designed to block monocyte recruitment or mobilization may be an effective adjuvant strategy for suppressing tumor metastasis in dogs with hemangiosarcoma. Introduction: Targeted chemotherapy can include repurposing drugs previously considered clinically irrelevant due to marked toxicity and low therapeutic index. Tubulysin is one such drug with compelling antiproliferative activity in vitro, but poor tolerability in vivo. High affinity folate receptor (FR) expression has previously been found in canine transitional cell carcinoma (TCC) and serve as a druggable target. A phase I clinical trial of Folate-Tubulysin was conducted in dogs with urinary tract TCC.